Floatz logo

Novo Rapid Insulin

Pulmonary Exacerbation

Hadassah Medical OrganizationN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Pulmonary Exacerbation cohort.

Asset / SponsorPhaseRating
ceftazidime
Association Nationale pour les Traitements A Domicile, les Innovations et la Recherche
Phase 4B
Diluent
Hadassah Medical Organization
N/AD
Insulin Aspart
Hadassah Medical Organization
N/AD

Same molecule, other indications

Novo Rapid Insulin is also rated in:

Cystic Fibrosis-related DiabetesDormant
B
Indicative ·
60 / 100
View asset →
cystic fibrosisDormant
D
Indicative ·
30 / 100
View asset →
prediabetes syndromeDormant
D
Indicative ·
30 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →